For first-line treatment of adult patients with locally advanced or metastatic EGFR+ NSCLC
COMBINED POWER TO CHANGE THE GAME IN EGFR+ mNSCLC1
RYBREVANT® + LAZCLUZE™ form the first and only chemotherapy-free, multitargeted combination to show statistically significant mPFS improvement vs osimertinib1
23.7 months (95% CI: 19.1, 27.7) vs 16.6 months (95% CI: 14.8, 18.5) for osimertinib; (HR=0.70 [95% CI: 0.58, 0.85]; P=0.0002)
NCCN CATEGORY 1 FIRST-LINE THERAPY2*
First-line amivantamab-vmjw (RYBREVANT®) + lazertinib (LAZCLUZE™) is an NCCN Category 1 recommended treatment option for patients with EGFR+† mNSCLC.‡§
Clinical experience in first line
Efficacy and safety profile of RYBREVANT® + LAZCLUZE™
See the results
Resources for you and your practice
Support your patients throughout their treatment journey
Learn more*EGFR mutation discovered prior to first-line systemic therapy.2
†EGFR exon 19 deletion or exon 21 L858R mutations.2
‡See the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for detailed recommendations, including other treatment options.2
§Prophylactic anticoagulation is recommended at the time of initiation to prevent venous thromboembolic events.2
CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; mNSCLC, metastatic non–small cell lung cancer; MOA, mechanism of action; mPFS, median progression-free survival; NSCLC, non–small cell lung cancer; PFS, progression-free survival.
References:
- RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed March 13, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
